Immunotherapy in Acute LymphoBLASTic Leukemia: TOWERing INOVATEions
This activity will provide an overarching review of ALL pathophysiology, diagnosis, and current treatment modalities in both the initial and relapsed/refractory setting. We will then discuss new literature surrounding the use of both inotuzumab ozogamicin and blinatumomab in ALL, and where these treatments fall into our current practice. This activity will provider pharmacists the opportunity revisit the management of patients with ALL, in particular, for those who practice outside of the scope of oncology. Additionally, attendees will be granted the opportunity to apply the knowledge gained in regards to our new immunotherapy options through active learning activities and open discussion.
- Review the pathophysiology, clinical manifestations, and current treatment modalities for acute lymphoblastic leukemia (ALL)
- Define minimal residual disease (MRD), and describe its utility in guiding treatment decisions for patient with ALL
- Discuss the role of emerging immunotherapy options in the treatment of ALL
- Evaluate current literature surrounding the use of inotuzumab ozogamicin and blinatumomab in patients with ALL
- 1.00 ACPE Pharmacist
- 1.00 General CEU – Attendance